Epoch Investment Partners Inc. Boosts Holdings in Medpace Holdings, Inc. $MEDP

Epoch Investment Partners Inc. raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 386.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 140,959 shares of the company’s stock after purchasing an additional 112,001 shares during the period. Epoch Investment Partners Inc. owned 0.49% of Medpace worth $67,687,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MEDP. Empirical Finance LLC raised its position in shares of Medpace by 81.0% in the first quarter. Empirical Finance LLC now owns 12,663 shares of the company’s stock worth $6,081,000 after buying an additional 5,667 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Medpace during the first quarter valued at $3,041,000. Renaissance Technologies LLC grew its position in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after buying an additional 38,760 shares in the last quarter. Public Employees Retirement System of Ohio grew its position in Medpace by 12.1% during the first quarter. Public Employees Retirement System of Ohio now owns 17,968 shares of the company’s stock worth $8,628,000 after buying an additional 1,941 shares in the last quarter. Finally, Compound Planning Inc. grew its position in Medpace by 8.2% during the first quarter. Compound Planning Inc. now owns 1,432 shares of the company’s stock worth $688,000 after buying an additional 108 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the company. BMO Capital Markets raised their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday. Royal Bank Of Canada upped their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $560.92.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 20.50% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Medpace Stock Performance

Shares of MEDP opened at $601.38 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a market cap of $17.18 billion, a price-to-earnings ratio of 35.25, a PEG ratio of 2.96 and a beta of 1.15. The firm has a 50 day moving average price of $492.09 and a 200-day moving average price of $494.49.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 17.45 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.